Cite
HARVARD Citation
Tanaka, Y. et al. (n.d.). FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the rheumatic diseases. p. 372. [Online].